As such, the PI3K delta inhibitor, idelalisib, which affects MYC protein stability [157], is currently being investigated in a phase II clinical trial for R/R DLBCL (NCT03576443), although preliminary data show only limited response rates [158]. Here, PIK3CD is linked to diffuse large B-cell lymphoma.